Fig. 4: Human IgG transgenic minipigs are tolerant to human IgG1 antibodies with a low clinical immunogenicity rate.
From: A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies
a, Schematic outline of the immunization strategy without adjuvant. Blood samples for ADA analysis are drawn before each treatment. b, Porcine IgG anti-bevacizumab antibody titre after immunization of 6 hIgG transgenic (TG) founder minipigs and 6 WT controls with bevacizumab. Data summarized from 3 individual studies, each with 2 transgenic and 2 WT minipigs. c, Porcine IgG anti-bevacizumab antibody titre after immunization of 4 hIgG transgenic minipigs from the F1 generation and 4 WT animals with bevacizumab. d, OD of porcine IgG anti-daratumumab antibodies measured via ELISA in minipigs (TG, n = 4; WT, n = 4) immunized with daratumumab. The dotted red line indicates an arbitrary threshold at a titre of 200 or mean + 6×s.d. threshold in the case of OD. Statistical analysis by 2-way ANOVA. Horizontal bar represents median. Each data point represents a biological replicate.
